Ultra high dose rate (35 Gy/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome.
Animals
Female
Gamma Rays
/ adverse effects
Gastrointestinal Diseases
/ etiology
Heart
/ radiation effects
Lymphocytes
/ immunology
Lymphopenia
/ etiology
Male
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Organs at Risk
/ radiation effects
Pancreatic Neoplasms
/ pathology
Radiation Injuries
/ etiology
Spleen
/ immunology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 11 2019
20 11 2019
Historique:
received:
08
05
2019
accepted:
04
11
2019
entrez:
22
11
2019
pubmed:
22
11
2019
medline:
13
11
2020
Statut:
epublish
Résumé
Recent reports have shown that very high dose rate radiation (35-100 Gy/second) referred to as FLASH tends to spare the normal tissues while retaining the therapeutic effect on tumor. We undertook a series of experiments to assess if ultra-high dose rate of 35 Gy/second can spare the immune system in models of radiation induced lymphopenia. We compared the tumoricidal potency of ultra-high dose rate and conventional dose rate radiation using a classical clonogenic assay in murine pancreatic cancer cell lines. We also assessed the lymphocyte sparing potential in cardiac and splenic irradiation models of lymphopenia and assessed the severity of radiation-induced gastrointestinal toxicity triggered by the two dose rate regimes in vivo. Ultra-high dose rate irradiation more potently induces clonogenic cell death than conventional dose rate irradiation with a dose enhancement factor at 10% survival (DEF
Identifiants
pubmed: 31748640
doi: 10.1038/s41598-019-53562-y
pii: 10.1038/s41598-019-53562-y
pmc: PMC6868225
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17180Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008280
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA216468
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : U01CA216468
Pays : International
Commentaires et corrections
Type : ErratumIn
Références
Cancer Res. 1979 Mar;39(3):840-3
pubmed: 427773
Radiother Oncol. 2018 Jul;128(1):154-160
pubmed: 29248170
Radiat Oncol. 2017 May 30;12(1):90
pubmed: 28558844
Sci Transl Med. 2014 Jul 16;6(245):245ra93
pubmed: 25031268
Radiother Oncol. 2018 Dec;129(3):582-588
pubmed: 30177374
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):142-151
pubmed: 30227198
Radiother Oncol. 2016 Feb;118(2):330-4
pubmed: 26653356
Clin Transl Radiat Oncol. 2018 Jan 31;9:23-29
pubmed: 29594247
Radiother Oncol. 2017 Sep;124(3):365-369
pubmed: 28545957
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):128-135
pubmed: 28816138
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1179-84
pubmed: 21601995
Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1084-1091
pubmed: 25035212
Acta Oncol. 2011 Aug;50(6):838-50
pubmed: 21767183
Am J Clin Oncol. 2015 Jun;38(3):259-65
pubmed: 23648440
Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):195-203
pubmed: 27816362
Cancer. 2005 Sep 15;104(6):1129-37
pubmed: 16080176
Anticancer Res. 2016 Jul;36(7):3541-7
pubmed: 27354621
Radiother Oncol. 2019 Oct;139:51-55
pubmed: 30850209
Proc Natl Acad Sci U S A. 2019 May 28;116(22):10943-10951
pubmed: 31097580
In Vivo. 2018 Nov-Dec;32(6):1519-1525
pubmed: 30348711
Radiother Oncol. 2019 Oct;139:18-22
pubmed: 31303340
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):323-332
pubmed: 28068240
Med Phys. 2010 Oct;37(10):5376-81
pubmed: 21089773
Clin Cancer Res. 2019 Jan 1;25(1):35-42
pubmed: 29875213
Clin Cancer Res. 2011 Aug 15;17(16):5473-80
pubmed: 21737504
Radiother Oncol. 2019 Oct;139:46-50
pubmed: 31266652
Radiother Oncol. 2019 Oct;139:4-10
pubmed: 31253467
Cancer Invest. 2012 Oct;30(8):571-6
pubmed: 22812722
Crit Rev Oncol Hematol. 2018 Mar;123:42-51
pubmed: 29482778
Radiother Oncol. 2018 Sep;128(3):584-590
pubmed: 29530432